Insmed Incorporated (INSM)
| Market Cap | 24.11B +91.1% |
| Revenue (ttm) | 819.56M +115.1% |
| Net Income | -1.18B |
| EPS | -5.70 |
| Shares Out | 216.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,383,108 |
| Open | 103.65 |
| Previous Close | 103.89 |
| Day's Range | 103.46 - 112.83 |
| 52-Week Range | 64.85 - 212.75 |
| Beta | 0.89 |
| Analysts | Strong Buy |
| Price Target | 200.17 (+79.98%) |
| Earnings Date | May 7, 2026 |
About INSM
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 ... [Read more]
Financial Performance
In 2025, Insmed's revenue was $606.42 million, an increase of 66.73% compared to the previous year's $363.71 million. Losses were -$1.28 billion, 39.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for INSM stock is "Strong Buy." The 12-month stock price target is $200.17, which is an increase of 79.98% from the latest price.
News
Insmed earnings selloff a buying opportunity, says H.C. Wainwright
H.C. Wainwright views the post-earnings selloff in shares of Insmed (INSM) as a buying opportunity. The “core Brinsupri launch thesis remains intact,” the analyst tells investors in a research note.
Insmed price target lowered to $185 from $200 at Raymond James
Raymond James lowered the firm’s price target on Insmed (INSM) to $185 from $200 and keeps an Outperform rating on the shares.
Insmed price target lowered to $226 from $230 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on Insmed (INSM) to $226 from $230 and keeps a Buy rating on the shares. The firm’s target cut is largely…
Insmed price target lowered to $160 from $177 at Wells Fargo
Wells Fargo lowered the firm’s price target on Insmed (INSM) to $160 from $177 and keeps an Overweight rating on the shares. The firm thinks shares were weak on concerns…
Insmed pullback a buying opportunity, says Roth Capital
The 20% share decline in Insmed (INSM) shares post print reflects investor concern about limited visibility into Brinsupri’s organic demand trajectory, prescribing trends, and payer durability rather ...
Insmed reports Q1 EPS (76c), consensus ($1.00)
Reports Q1 revenue $306.0M, consensus $300.8M. “In the first quarter of 2026, momentum across Insmed’s (INSM) commercial portfolio and pipeline continued to build,” said CEO Will Lewis. “The trajector...
Insmed Earnings Call Transcript: Q1 2026
BRINSUPRI delivered exceptional sequential growth and is on track for $1B+ in 2026 revenue, with strong payer access, high compliance, and expanding prescriber base. ARIKAYCE and TPIP also advanced, while robust cash reserves support continued execution and pipeline growth.
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
— Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Qua...
Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
— Insmed's Educational Initiative, Suspect Bronchiectasis (Suspect BE), Aims to Elevate Recognition and Diagnosis of Bronchiectasis and Encourage Conversations with a Pulmonologist — — Bronchiectasis ...
Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026
—New Data in Non-Cystic Fibrosis Bronchiectasis Further Define Impact of BRINSUPRI ® on Respiratory Symptoms— —Findings from a Pharmacokinetic Study Continue to Support Further Evaluation of Treprosti...
Insmed price target raised to $214 from $212 at BofA
BofA raised the firm’s price target on Insmed (INSM) to $214 from $212 and keeps a Buy rating on the shares. After having conducted an updated prescriber survey to gauge…
Insmed to Present at May 2026 Investor Conferences
BRIDGEWATER, N.J., April 30, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor...
Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
BRIDGEWATER, N.J., April 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor...
Insmed discontinues development of skin condition drug after mid-stage study miss
Insmed said on Tuesday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial.
Insmed Provides Clinical Update on Phase 2b CEDAR Study
—Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either Dose...
Insmed Transcript: Study result
The ENCORE phase III trial showed ARIKAYCE plus standard therapy significantly improved respiratory symptoms and culture conversion rates in newly diagnosed or recurrent MAC lung infection, with a favorable safety profile and lower discontinuation rates. These results support regulatory submissions for label expansion and could establish ARIKAYCE as a new standard of care.
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
—The Study Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Improvements in Respiratory Symptom Sco...
Insmed Transcript: Leerink Global Healthcare Conference 2026
The company is advancing a diversified pipeline with two commercial products, major clinical readouts for ARIKAYCE and brensocatib, and a robust launch strategy targeting significant patient populations. TPIP and early-stage assets offer additional growth, with multiple phase 3 programs underway.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., March 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
Insmed Transcript: TD Cowen 46th Annual Health Care Conference
Q4 revenue far exceeded expectations, driven by broad physician adoption and strong patient outcomes. Growth is expected to continue as positive experiences drive deeper prescribing, with future upside from broader patient populations and pipeline catalysts.
Insmed Earnings Call Transcript: Q4 2025
2025 saw a transformative launch for BRINSUPRI, driving strong revenue growth and positioning for at least $1B in 2026, while ARIKAYCE and TPIP also advanced. Cash flow positivity is expected without new capital, and market access for BRINSUPRI remains highly favorable.
Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
—Company Expects Full-Year 2026 BRINSUPRI® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE ® (amikacin liposome inhalation suspension) Revenue Guidance of $450 Mil...
Insmed To Present at March 2026 Investor Conferences
BRIDGEWATER, N.J., Feb. 13, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026
BRIDGEWATER, N.J., Feb. 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
—Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging Analysis from the Phase 2b Study in Pulmona...